Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus homoharringtonine for newly diagnosed unfit AML
ChiCTR2200060782Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2022
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and homoharringtonine in acute myeloid leukemia (AML), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall response rate. Started Jun 2022; status: recruiting.
02
Drugs
venetoclaxhomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200060782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060782.